Structural Changes of Cutaneous Immune Cells in Patients With Type 1 Diabetes and Their Relationship With Diabetic Polyneuropathy

Background and Objectives Diabetic polyneuropathy (DPN) is a complication of diabetes characterized by pain or lack of peripheral sensation, but the underlying mechanisms are not yet fully understood. Recent evidence showed increased cutaneous macrophage infiltration in patients with type 2 diabetes and painful DPN, and this study aimed to understand whether the same applies to type 1 diabetes. Methods The study included 104 participants: 26 healthy controls and 78 participants with type 1 diabetes (participants without DPN [n = 24], participants with painless DPN [n = 29], and participants with painful DPN [n = 25]). Two immune cells, dermal IBA1+ macrophages and epidermal Langerhans cells (LCs, CD207+), were visualized and quantified using immunohistological labeling and stereological counting methods on skin biopsies from the participants. The IBA1+ macrophage infiltration, LC number density, LC soma cross-sectional area, and LC processes were measured in this study. Results Significant difference in IBA1+ macrophage expression was seen between the groups (p = 0.003), with lower expression of IBA1 in participants with DPN. No differences in LC morphologies (LC number density, soma cross-sectional area, and process level) were found between the groups (all p > 0.05). In addition, IBA1+ macrophages, but not LCs, correlated with intraepidermal nerve fiber density, Michigan neuropathy symptom inventory, (questionnaire and total score), severity of neuropathy as assessed by the Toronto clinical neuropathy score, and vibration detection threshold in the whole study cohort. Discussion This study showed expressional differences of cutaneous IBA1+ macrophages but not LC in participants with type 1 diabetes–induced DPN compared with those in controls. The study suggests that a reduction in macrophages may play a role in the development and progression of autoimmune-induced diabetic neuropathy.

[1]  S. Sindrup,et al.  Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[2]  M. Dalakas.  Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies , 2022, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.

[3]  J. Nyengaard,et al.  Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[4]  A. Kawabata,et al.  Macrophage as a Peripheral Pain Regulator , 2021, Cells.

[5]  A. Boulton,et al.  Small Nerve Fiber Damage and Langerhans Cells in Type 1 and Type 2 Diabetes and LADA Measured by Corneal Confocal Microscopy , 2021, Investigative ophthalmology & visual science.

[6]  J. Classen,et al.  Treatment-Induced Neuropathy in Diabetes (TIND)—Developing a Disease Model in Type 1 Diabetic Rats , 2021, International journal of molecular sciences.

[7]  Kaori H. Yamada,et al.  VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration , 2021, Investigative ophthalmology & visual science.

[8]  T. Jensen,et al.  Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes , 2019, Pain.

[9]  D. Zochodne.  The challenges of diabetic polyneuropathy: a brief update. , 2019, Current opinion in neurology.

[10]  T. Jensen,et al.  Painful and non‐painful diabetic polyneuropathy: Clinical characteristics and diagnostic issues , 2019, Journal of diabetes investigation.

[11]  P. Nawroth,et al.  Structure-function relationships in peripheral nerve contributions to diabetic peripheral neuropathy. , 2019, Pain.

[12]  Yu-yan Xu,et al.  The risk factors for diabetic peripheral neuropathy: A meta-analysis , 2019, PloS one.

[13]  M. Banerjee,et al.  Diabetes and obesity are the main metabolic drivers of peripheral neuropathy , 2018, Annals of clinical and translational neurology.

[14]  H. Hammad,et al.  Langerhans Cells: Sensing the Environment in Health and Disease , 2018, Front. Immunol..

[15]  K. Nagao,et al.  Langerhans Cells - The Macrophage in Dendritic Cell Clothing. , 2017, Trends in immunology.

[16]  M. Collin,et al.  Langerhans cell origin and regulation , 2016, Current opinion in hematology.

[17]  J. Nyengaard,et al.  Structural and functional assessment of skin nerve fibres in small‐fibre pathology , 2015, European journal of pain.

[18]  Peter G Smith,et al.  Langerhans cells regulate cutaneous innervation density and mechanical sensitivity in mouse footpad , 2014, Neuroscience Letters.

[19]  M. Roden,et al.  Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes , 2014, Diabetes.

[20]  M. Vizcaychipi,et al.  Neuroinflammation: The role and consequences , 2014, Neuroscience Research.

[21]  C. Eleazu,et al.  Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans , 2013, Journal of Diabetes & Metabolic Disorders.

[22]  J. Miyan,et al.  CNS inflammation and bone marrow neuropathy in type 1 diabetes. , 2013, The American journal of pathology.

[23]  Zheng-wang Chen,et al.  Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. , 2013, Cellular immunology.

[24]  D. Bender,et al.  Neurogenic factor-induced Langerhans cell activation in diabetic mice with mechanical allodynia , 2013, Journal of Neuroinflammation.

[25]  Andre Pascal Kengne,et al.  Diabetes Mellitus and Inflammation , 2013, Current Diabetes Reports.

[26]  L. Dimeglio,et al.  Type 1 Diabetes , 2019, Epidemiology of Diabetes.

[27]  P. Smith,et al.  Nerve-Langerhans cell interactions in diabetes and aging. , 2012, Histology and histopathology.

[28]  J. Valls-Solé,et al.  Epidermal Langerhans cells in small fiber neuropathies , 2012, PAIN®.

[29]  A. Boulton,et al.  Increased Langerhan cell density and corneal nerve damage in diabetic patients: role of immune mechanisms in human diabetic neuropathy. , 2011, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[30]  Rayaz A. Malik,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[31]  C. Schmitz,et al.  Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study , 2010, Journal of the peripheral nervous system : JPNS.

[32]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[33]  Yong Zhao,et al.  Allograft inflammatory factor-1 and its immune regulation , 2007, Autoimmunity.

[34]  H. Kamiya,et al.  Diabetic Neuropathy Differs in Type 1 and Type 2 Diabetes , 2006, Annals of the New York Academy of Sciences.

[35]  K. Gillespie.  Type 1 diabetes: pathogenesis and prevention , 2006, Canadian Medical Association Journal.

[36]  D. Yue,et al.  The relationship among pain, sensory loss, and small nerve fibers in diabetes. , 2006, Diabetes care.

[37]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[38]  N. Özsoy,et al.  Ultrastructural determination of gingival Langerhans cells in alloxan‐induced diabetic rats , 2005, Cell biochemistry and function.

[39]  Michael Stumvoll,et al.  Type 2 diabetes: principles of pathogenesis and therapy , 2005, The Lancet.

[40]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[41]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[42]  P. Mouton,et al.  Number of Langerhans immune cells in painful and non-painful human skin after shingles , 2003, Archives of Dermatological Research.

[43]  D. Jacobowitz,et al.  Stiff person syndrome: Advances in pathogenesis and therapeutic interventions , 2001, Neurology.

[44]  Y. Imai,et al.  A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. , 1996, Biochemical and biophysical research communications.

[45]  R. Arceci,et al.  Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. , 1995, The Journal of clinical investigation.

[46]  H. J. G. Gundersen,et al.  The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[47]  P. Dyck,et al.  Vasculitic Neuropathies , 2015, Current Treatment Options in Neurology.

[48]  Carl Nathan,et al.  Nonresolving Inflammation , 2010, Cell.

[49]  Z. Kazibutowska,et al.  [Neuropathy and type 1 diabetes mellitus]. , 2008, Pediatric Endocrinology Diabetes and Metabolism.